Calidi Biotherapeutics (CLDI) Total Non-Current Liabilities (2021 - 2025)

Calidi Biotherapeutics has reported Total Non-Current Liabilities for 5 years, with the latest figure at $5.0 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 58.77% year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2025 stood at $5.0 million (down 58.77% YoY), and the FY2025 full-year result was $5.0 million, down 58.77% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $5.0 million, down from $6.6 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $21.3 million in Q1 2024, with the low at $1.1 million in Q4 2022.
• Average Total Non-Current Liabilities over 5 years is $10.9 million, with a median of $9.7 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities tumbled 93.32% in 2022 and soared 1545.86% in 2023.
• Tracing CLDI's Total Non-Current Liabilities over 5 years: stood at $16.0 million in 2021, then plunged by 93.32% to $1.1 million in 2022, then soared by 1545.86% to $17.6 million in 2023, then plunged by 31.45% to $12.1 million in 2024, then slumped by 58.77% to $5.0 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $5.0 million (Q4 2025), $6.6 million (Q3 2025), and $7.2 million (Q2 2025), per Business Quant data.

Peer Comparison